Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.

TitleIrreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.
Publication TypeJournal Article
Year of Publication2012
AuthorsJosé, A, Sobrevals, L, Ivorra, A, Fillat, C
JournalCancer letters
Volume317
Pagination16–23
ISSN1872-7980
KeywordsAlanine Transaminase, Alanine Transaminase: blood, Amylases, Amylases: blood, Animals, Aspartate Aminotransferases, Aspartate Aminotransferases: blood, Biological Markers, Biological Markers: blood, Blood Glucose, Blood Glucose: metabolism, Carcinoma, Cell Line, Cell Proliferation, Electrochemotherapy, Electrochemotherapy: adverse effects, Feasibility Studies, Genes, Humans, Lipase, Lipase: blood, Luminescent Measurements, Male, Mice, Microvessels, Microvessels: pathology, Necrosis, Nude, Pancreatic Ductal, Pancreatic Ductal: blood, Pancreatic Ductal: blood supply, Pancreatic Ductal: genetics, Pancreatic Ductal: pathology, Pancreatic Ductal: therapy, Pancreatic Neoplasms, Pancreatic Neoplasms: blood, Pancreatic Neoplasms: blood supply, Pancreatic Neoplasms: genetics, Pancreatic Neoplasms: pathology, Pancreatic Neoplasms: therapy, Reporter, Time Factors, Transfection, Tumor, Xenograft Model Antitumor Assays
Abstract

Pancreatic ductal adenocarcinoma (PDAC) therapies show limited success. Irreversible electroporation (IRE) is an innovative loco-regional therapy in which high-voltage pulses are applied to induce plasma membrane defects leading to cellular death. In the present study we evaluated the feasibility of IRE against PDAC. IRE treatment exhibited significant antitumor effects and prolonged survival in mice with orthotopic xenografts. Extensive tumor necrosis, reduced tumor cell proliferation and disruption of microvessels were observed at different days post-IRE. Animals had transient increases in transaminases, amylase and lipase enzymes that normalized at 24h post-IRE. These results suggest that IRE could be an effective treatment for locally advanced pancreatic tumors.

URLhttp://www.ncbi.nlm.nih.gov/pubmed/22079741
DOI10.1016/j.canlet.2011.11.004